Piramal Critical Care launches first-to-market generic zinc sulfate injection in US
Zinc Sulfate is a trace element indicated as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated
Piramal Pharma’s Critical Care business, a leading Complex Hospital Generics company, announces the first-to-market generic US launch of Zinc Sulfate Injection. This product is US Food and Drug Administration approved with Competitive Generic Therapy (CGT) designation; an approval pathway intended to enhance market competition for sole source drugs. Zinc Sulfate is a trace element indicated as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. This intravenous nutritional injection is available in two strengths – 30mg/10mL (3mg/mL) and 25mg/5mL (5mg/mL).
Peter DeYoung, CEO, Piramal Global Pharma commented, “At Piramal Critical Care (PCC), we are excited to launch our first CGT-designated product to support our core purpose of providing the market with drugs that contribute to saving and improving patients’ lives. Zinc Sulfate Injection joins our growing US portfolio of injectable products, complementing our market-leading inhaled anaesthesia products, as we strive to deliver critical care solutions to patients and healthcare providers around the world.”
In addition to the recent launch of Zinc Sulfate injection, over the past several years PCC has launched a broad line of critical generic injectables in the US market, including Ampicillin and Sulbactam for Injection, USP, Dexmedetomidine Injection, USP, Dexmedetomidine HCl Injection, USP, Glycopyrrolate Injection, USP, Rocuronium Bromide Injection, and Succinylcholine Chloride Injection, USP. PCC’s full product portfolio is available at piramalcriticalcare.com.
Through the ongoing expansion of its portfolio, PCC continues to strengthen its commitment to delivering high-quality products to healthcare providers and their patients around the world.
